These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28448368)

  • 1. Managing Chemotherapy-Induced Anemia with Erythropoiesis-Stimulating Agents Plus Iron.
    Whitehead L
    Am J Nurs; 2017 May; 117(5):67. PubMed ID: 28448368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.
    Mhaskar R; Djulbegovic B
    JAMA Oncol; 2016 Nov; 2(11):1499-1500. PubMed ID: 27387766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
    Henry DH; Dahl NV; Auerbach MA
    Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoiesis-stimulating agents in ovarian cancer patients receiving chemotherapy: to treat or not to treat?
    Marchetti C; Palaia I; Benedetti Panici P
    Int J Gynecol Cancer; 2013 Jun; 23(5):783-4. PubMed ID: 23694979
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
    Szucs TD; Blank PR; Schwenkglenks M; Aapro M
    Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia in cancer: update on studies of erythropoiesis-stimulating agents.
    Burstein HJ
    J Support Oncol; 2007 Apr; 5(4 Suppl 2):5-26. PubMed ID: 17550053
    [No Abstract]   [Full Text] [Related]  

  • 8. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.
    Shord SS; Hamilton JM; Cuellar S
    J Oncol Pharm Pract; 2008 Mar; 14(1):5-22. PubMed ID: 18337436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
    Wauters I; Vansteenkiste J
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
    Schiavetto I; Pedrazzoli P; Basilico V; Siena S
    Chemotherapy; 2008; 54(6):417-20. PubMed ID: 18824846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.
    Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):179-87. PubMed ID: 21972052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should intravenous iron be the standard of care in oncology?
    Auerbach M
    J Clin Oncol; 2008 Apr; 26(10):1579-81. PubMed ID: 18375888
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
    Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R
    J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on safety of ESAs in cancer-induced anemia.
    Glaspy J
    J Natl Compr Canc Netw; 2012 May; 10(5):659-66. PubMed ID: 22570294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summaries of nursing care-related systematic reviews from the Cochrane library: erythropoiesis-stimulating agents for anemia in chronic heart failure patients.
    Barrett D
    J Cardiovasc Nurs; 2010; 25(5):381-2. PubMed ID: 20714234
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.
    Vekeman F; Bookhart BK; White J; McKenzie RS; Duh MS; Piech CT; Lefebvre P
    Transfusion; 2009 May; 49(5):895-902. PubMed ID: 19175548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iron in chemotherapy-induced anemia.
    Auerbach M
    Am J Hematol; 2014 Dec; 89(12):1153. PubMed ID: 25359517
    [No Abstract]   [Full Text] [Related]  

  • 19. Darbepoetin alfa and history of thromboembolic events.
    Ferretti G; Felici A; Cognetti F
    J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of a Patient Blood Management Program and an Outpatient Anemia Management Protocol on Red Cell Transfusions in Oncology Inpatients and Outpatients.
    Gross I; Trentino KM; Andreescu A; Pierson R; Maietta RA; Farmer S
    Oncologist; 2016 Mar; 21(3):327-32. PubMed ID: 26865590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.